American journal of veterinary research · 2025
Comparison of multiple drug regimens for reduction of synovitis-induced lameness pain in meat-type goats.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Weeder Mikaela M, Kleinhenz Michael D, Reppert Emily J, Curtis Andrew K, Viscardi Abbie V, Leslie Ally, Bear Misty, Fritz Bailey, Dahmer Payton, Coetzee Johann F
Аннотация
OBJECTIVE: This study evaluated the analgesic effects of firocoxib, meloxicam, and transdermal flunixin in meat-type goats with experimentally induced lameness.
METHODS: 44 crossbred castrated meat-type goats with an average weight of 35 kg (range, 25 to 43 kg) were enrolled from June to December 2022. Lameness was induced with amphotericin B injected in the distal interphalangeal joint of the left hind lateral claw. After a washout period, lameness was reproduced in the right hind limb. Eleven treatment groups were implemented: firocoxib (0.5, 1.0, and 2.0 mg/kg), meloxicam (1.0, 2.0, and 3.0 mg/kg, transdermal flunixin (3.3, 4.2, and 5.0 mg/kg), and positive and negative control. Outcome measurements included infrared thermography, mechanical nociception threshold, plasma cortisol, plasma substance P, kinetic gait analysis, visual lameness scoring, and visual analog scoring and were collected at -24, 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours relative to lameness induction.
RESULTS: Transdermal flunixin at 3.3 and 5.0 mg/kg demonstrated the greatest analgesic effects from outcome measurements collected.
CONCLUSIONS: Transdermal flunixin meglumine provides the most effective analgesia for goats with induced lameness, suggesting it may be the preferred option for pain relief in goats with lameness symptoms.
CLINICAL RELEVANCE: Transdermal flunixin meglumine at 3.3 or 5.0 mg/kg provided the best results for pain mitigation in goats with induced lameness.
METHODS: 44 crossbred castrated meat-type goats with an average weight of 35 kg (range, 25 to 43 kg) were enrolled from June to December 2022. Lameness was induced with amphotericin B injected in the distal interphalangeal joint of the left hind lateral claw. After a washout period, lameness was reproduced in the right hind limb. Eleven treatment groups were implemented: firocoxib (0.5, 1.0, and 2.0 mg/kg), meloxicam (1.0, 2.0, and 3.0 mg/kg, transdermal flunixin (3.3, 4.2, and 5.0 mg/kg), and positive and negative control. Outcome measurements included infrared thermography, mechanical nociception threshold, plasma cortisol, plasma substance P, kinetic gait analysis, visual lameness scoring, and visual analog scoring and were collected at -24, 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours relative to lameness induction.
RESULTS: Transdermal flunixin at 3.3 and 5.0 mg/kg demonstrated the greatest analgesic effects from outcome measurements collected.
CONCLUSIONS: Transdermal flunixin meglumine provides the most effective analgesia for goats with induced lameness, suggesting it may be the preferred option for pain relief in goats with lameness symptoms.
CLINICAL RELEVANCE: Transdermal flunixin meglumine at 3.3 or 5.0 mg/kg provided the best results for pain mitigation in goats with induced lameness.